Increased Survival of Glioblastoma Patients Who Respond to Antiangiogenic Therapy with Elevated Blood Perfusion
Year: 2011
Type: article
Abstract: The abnormal vasculature of the tumor microenvironment supports progression and resistance to treatment. Judicious application of antiangiogenic therapy may normalize the structure and function of the tumor vasculature, promoting improved blood perfusion. However, direct clinical evidence is lacking for improvements in blood perfusion after antiangiogenic therapy. In this study, we used MRI to assess tumor blood perfusion in 30 recurrent glioblastoma patients who were undergoing treatment with cediranib, a pan-VEGF receptor tyrosine kinase inhibitor. Tumor blood perfusion increased durably for more than 1 month in 7 of 30 patients, in whom it was associated with longer survival. Together, our findings offer direct clinical evidence in support of the hypothesis that vascular normalization can increase tumor perfusion and help improve patient survival.
Source: Cancer Research
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: green
Awards: A Phase 2 study of AZD2171 in Recurrent Glioblastoma, G2227408383, Harvard Clinical and Translational Science Center (UL1), General Clinical Research Center, G393103480, Toward Multi-Center MR Brain Perfusion, Integrative Pathophysiology of Solid Tumors, Quantitative MR-PET for Therapy Assessment in Glioma Patients, Computeserver Structural &Functional Image Analysis, Clinical and Molecular Studies of Malignant Brain Tumors, A Siemens MAGNETOTOM Trio 3 Tesla MRI System, A 3.0 Tesla MRI System in a Neuroscience ICU, Angiogenesis-targeting therapy for glioblastoma, A Storage Area Network for Structural and Functional Image Analysis, Silicon Graphics Prism Extreme 128P/1TB
OpenAlex ID: W2134431790